Telix Pharmaceuticals Ltd (TLX)

Good insider buying!
https://finance.yahoo.com/markets/stocks/articles/insider-buying-telix-pharmaceuticals-co-205051753.html

TLX101-Px (Pixlumi®) MAA Accepted in EuropeApril 30, 2026 9:07 PM
PR Newswire (US)

MELBOURNE, Australia and INDIANAPOLIS, May 1, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the marketing authorization application (MAA) filed in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate[1], has been validated and accepted for review.
The application, covering commercially significant European markets[2], has now moved into a 210-day active assessment phase[3]. Telix is seeking to expand patient access to advanced brain imaging through a broad clinical label, reflective of current clinical practice guidelines[4]. Assuming a positive outcome from the application at Day 210, national marketing authorizations are expected to follow shortly after.In Europe, there is currently no generally available commercial product for PET[5] imaging of glioma with 18F-FET ("FET-PET"), resulting in an acute and immediate need for a consistent, high-quality product [6]. Through this MAA, Telix aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications. TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate TLX101-Tx (iodofalan 131I), which has been granted orphan drug designation in Europe and the U.S. The Phase 3 IPAX-BrIGHT[7] trial of TLX101-Tx in patients with recurrent glioblastoma has commenced patient dosing internationally[8] and is launching in multiple European countries.Sied Kebir, MD, Head of Clinical Neuro-Oncology, University Hospital Essen, said: "In our day-to-day practice, one of the hardest questions we face is whether a change on conventional imaging reflects tumor progression or a treatment-related effect. PET imaging with ¹8F-FET can be used to help resolve this dilemma. The acceptance of this application is a welcome step toward broader, standardized patient access across Europe, and more timely and accurate decision-making."Raphaël Ortiz, Chief Executive Officer, Telix International, commented, "The acceptance of our European MAA represents a significant regulatory milestone for Telix and for TLX101-Px. It supports a critical unmet need for widely accessible glioma imaging for both diagnostic evaluation and therapeutic decision-making. Subject to regulatory approval, we are preparing to bring this powerful precision medicine product to market in both Europe and the United States, where our new drug application has recently been accepted[9]."About glioma in EuropeIn Europe, approximately 67,500 brain and central nervous system tumors are diagnosed every year[10], with gliomas accounting for approximately 30% of these, and up to 80% of all malignant brain tumors[11]. There is a critical unmet need to improve the diagnosis and management of gliomas, which are the most common primary brain tumors of the central nervous system, particularly in the post-treatment setting4. Conventional MRI imaging techniques have several limitations, including a lack of biological specificity, dependency on blood-brain barrier disruption, and an inherent inability to differentiate between tumor progression or treatment-related causes. This can yield inconclusive results and delay time-sensitive treatment decisions[12]. With low survival rates and the need to make rapid decisions, precision imaging is paramount6. Subject to regulatory approval, TLX101-Px has the potential to address this need, enabling patients in Europe and worldwide to receive greater clarity in their diagnosis and treatment decision making.About TLX101-Px TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine) is Telix's PET imaging candidate for the characterization of glioma. TLX101-Px targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). This enables TLX101-Px to be potentially utilized as a patient selection and response assessment tool for TLX101-Tx (iodofalan 131I), Telix's LAT1-targeting glioblastoma (GBM) therapy candidate, currently under investigation in Telix's IPAX-2[13] and IPAX-BrIGHT studies. TLX101-Px and TLX101-Tx have not received marketing authorizations in any jurisdiction. In relevant European markets, the proposed brand name for TLX101-Px is "Pixlumi®". Brand name and commercial launch are subject to final regulatory approval.About Telix Pharmaceuticals Limited Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.Telix Investor Relations (Global)Ms. Kyahn WilliamsonSVP Investor Relations and Corporate Communicationskyahn.williamson@telixpharma.comTelix Investor Relations (U.S.)? Ms. Annie Kasparian? Director Investor Relations and Corporate Communications? annie.kasparian@telixpharma.com Telix Investor Relations (Australia)Ms. Charlene JawAssociate Director Investor Relationscharlene.jaw@telixpharma.comLegal NoticesCautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. ?To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, including TLX101-Px, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.©2026 Telix Pharmaceuticals Limited. All rights reserved.[1] Telix ASX disclosure February 18, 2026.[2] The French National Agency for Medicines and Health Products Safety (ANSM), in its capacity as Reference Member State, is responsible for coordinating and leading the scientific evaluation of the dossier, in collaboration with the concerned Member States, nominated by Telix and representing the major European markets for Telix's brain cancer imaging product.[3] 210-day assessment phase excludes clock-stop.[4] Galldiks et al. Lancet Oncol. 2025 (Joint guidelines from the European Association of Nuclear Medicine (EANM), European Association of Neuro-Oncology (EANO), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Response Assessment in Neuro-Oncology (RANO), The European Society for Pediatric Oncology and The Response Assessment in Pediatric Neuro-Oncology for the characterization of recurrence in glioma patients); National Comprehensive Cancer Network® ("NCCN") Clinical Practice Guidelines in Oncology ("NCCN Guidelines®") for Central Nervous System Cancers V1.2025.[5] Positron emission tomography.[6] Albert et al. Lancet Oncol. 2024.[7] ClinicalTrials.gov ID: NCT07100730.[8] Telix media release April 15, 2026.[9] Telix ASX disclosure April 10, 2026.[10] Frosina et al. Sci Rep. 2024.[11] Goodenberger et al. Cancer Genetics. 2012.[12] Smith et al. J Nucl Med. 2023.[13] ClinicalTrials.gov ID: NCT05450744.Logo - https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg 



View original content:https://www.prnewswire.co.uk/news-releases/tlx101-px-pixlumi-maa-accepted-in-europe-302759731.html

Original: TLX101-Px (Pixlumi®) MAA Accepted in Europe

Telix Successfully Prices and Upsizes US$600 Million Convertible BondsApril 14, 2026 6:41 PM
PR Newswire (US)

MELBOURNE, Australia and Indianapolis, April 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) ("Telix") is pleased to announce that it has successfully priced and upsized its 1.50 per cent convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the "Issuer"), and guaranteed by Telix and Telix Pharmaceuticals (US) Inc. from US$550 million to US$600 million due to strong demand (the "Offering"). The convertible notes, also referred to as "convertible bonds" ("Convertible Bonds"), are convertible into fully paid ordinary shares in Telix ("Ordinary Shares"). The Offering received strong support from eligible investors globally.
The initial conversion price of the Convertible Bonds is US$13.85 (~A$19.55) per Ordinary Share, which represents a conversion premium of 37.5 per cent over the reference share price (A$14.22 per Ordinary Share), subject to anti-dilution adjustments set out in the final terms and conditions of the Convertible Bonds.The Convertible Bonds will bear interest at a rate of 1.50 per cent per annum. Interest will be payable quarterly in arrear on 22 January, 22 April, 22 July and 22 October in each year, beginning on 22 July 2026. The Convertible Bonds will mature on or about 22 April 2031, unless redeemed, repurchased, or converted in accordance with their terms.Under the reverse bookbuilding process announced by Telix on 14 April 2026 (the "Concurrent Repurchase"), Telix will concurrently repurchase approximately A$637 million of its existing A$650 million convertible bonds due 2029 ("Existing Convertible Bonds"). The Concurrent Repurchase will result in the repurchase and cancellation of more than 85% of the Existing Convertible Bonds. Telix intends to exercise its right to redeem the remaining Existing Convertible Bonds.Settlement of the Offering and the Concurrent Repurchase is expected on 22 April 2026 and is subject to satisfaction of customary conditions. The Existing Convertible Bonds that are to be repurchased will be cancelled in accordance with their terms and conditions.Managing Director and Group CEO, Dr. Christian Behrenbruch, said: "The successful completion of the convertible bonds refinance is in line with our capital management strategy and provides financial flexibility for Telix. We are pleased with the support we have received from both existing and new investors as part of the concurrent repurchase and new issue of convertible bonds." J.P. Morgan Securities plc ("J.P. Morgan") is Sole Bookrunner on the Offering and Sole Dealer Manager on the Concurrent Repurchase.J.P. Morgan completed the delta placement of Ordinary Shares at a clearing price of A$14.22 per Ordinary Share, which represents an 8.0 per cent discount to Telix's closing price of A$15.45 on 14 April 2026 and a 3.2 per cent discount to the 5-day volume weighted average price per share of A$14.69. This acts as the reference price to determine the initial conversion price of the Convertible Bonds.Key terms of the Convertible BondsIssuer Telix Pharmaceuticals (Investments) Inc.Guarantors Telix Pharmaceuticals Limited and Telix Pharmaceuticals (US)
Inc.Issue SizeUS$600 millionRankingDirect, unconditional, unsubordinated and unsecured obligations
of the Issuer and GuarantorsMaturity DateOn or about 22 April 2031 (5 years)Investor Put OptionAt the end of year 3Coupon / Yield 1.50% p.a.Conversion Premium37.5% above the Reference Share PriceReference Share PriceA$14.22 per Ordinary ShareConversion Price Adjustment Standard anti-dilutive adjustments including conversion price
adjustment for all dividends paid by TelixStock Borrow FacilityElk River Holdings Pty Ltd as the trustee for The Behrenbruch
Family Trust ("Stock Lender") in which Dr Behrenbruch holds an
indirect interest has entered into a stock lending agreement with
an affiliate of J.P. Morgan ("Stock Borrower") over 15 million
Ordinary Shares. The Stock Borrow Facility has a term of 11 months. Listing SGX-STSelling RestrictionsReg S (Cat 2) onlyAbout Telix Pharmaceuticals Limited Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.  Legal NoticesCautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including Australia, Singapore, and the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Neither this announcement nor any copy hereof may be taken into or distributed in the United States. The information contained in this announcement is not for distribution, directly or indirectly, in or into the United States. The Convertible Bonds, the guarantees and the Ordinary Shares to be issued upon conversion of the Convertible Bonds have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States and they may not be offered or sold, resold, transferred or delivered, directly or indirectly, within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. The Convertible Bonds and the guarantees are being offered and sold solely outside the United States in an "offshore transaction" as defined in, and in reliance on Regulation S under the Securities Act. Nothing in this announcement or anything attached to it shall form the basis of any contract or commitment. The Concurrent Repurchase is not being made and will not be made, directly or indirectly, in or into the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. The Existing Convertible Bonds may not be tendered in the Concurrent Repurchase by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States as defined in Regulation S of the Securities Act. Any purported tender of Existing Convertible Bonds made by a person located in the United States will not be accepted. This communication may not be distributed to the press or other media or forwarded, photocopied, passed on or, in any other manner, transmitted to any other person. Non-compliance with the foregoing may constitute a violation of law. This information is subject to change. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. ©2026 Telix Pharmaceuticals Limited. All rights reserved.Logo - https://mma.prnewswire.com/media/1920208/5916703/Telix_Main_Logo_Logo.jpg



View original content:https://www.prnewswire.co.uk/news-releases/telix-successfully-prices-and-upsizes-us600-million-convertible-bonds-302742409.html

Original: Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds

Telix Refinances Convertible BondsApril 14, 2026 4:34 AM
PR Newswire (US)

MELBOURNE, Australia and INDIANAPOLIS, Ind., April 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) ("Telix") today launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the "Issuer"), and guaranteed by Telix and Telix Pharmaceuticals (US) Inc. (the "Offering"). The convertible notes, also referred to as "convertible bonds" ("Convertible Bonds"), are convertible into fully paid ordinary shares in Telix ("Ordinary Shares").
Managing Director and Group CEO, Dr. Christian Behrenbruch, said: "The refinance of the existing Convertible Bonds represents our proactive approach to capital management. The new Convertible Bonds will continue to provide the business with cost effective financing."The new Convertible Bonds represent attractive, low-cost financing to Telix and are non-dilutive until any potential future conversions occur. The initial conversion price will be at a premium to Telix's current share price.After deduction of commissions, professional fees and other administrative expenses, it is intended that the net proceeds will be used to repurchase the existing convertible bonds due 2029 ("Existing Convertible Bonds"). Any funds raised above that required for the repurchase of the Existing Convertible Bonds will be applied to general corporate purposes.Convertible Bonds OfferingIt is intended that the Convertible Bonds will be listed on the Official List of Singapore Exchange Securities Trading Limited ("SGX-ST")The Offering is being marketed to eligible investors with the final terms of the Convertible Bonds to be determined via a bookbuild process expected to be completed prior to market open on Wednesday, 15 April 2026Concurrent with the Offering, a delta placement of Ordinary Shares will be executed to facilitate hedging activity by investors in relation to the Convertible Bonds. The clearing price per Ordinary Share under the delta placement will be used as the reference share price for the Convertible BondsMore details on the key terms of the Convertible Bonds are provided in the table belowStock Borrow FacilityTo assist the implementation of the Convertible Bonds Offering, Elk River Holdings Pty Ltd as the trustee for The Behrenbruch Family Trust[1] ("Stock Lender") intends to enter into a stock lending agreement with an affiliate of J.P. Morgan ("Stock Borrower") pursuant to which the Stock Lender will lend a certain number of Ordinary Shares to the Stock Borrower, and the Stock Borrower will be required to return the borrowed Ordinary Shares to the Stock Lender pursuant to the terms of the agreement ("Stock Borrow Facility").Concurrent RepurchaseAdditionally, Telix is conducting a reverse bookbuilding process to receive indications of interest from holders of the Existing Convertible Bonds on a repurchase of the outstanding Existing Convertible Bonds ("Concurrent Repurchase"). The number of Existing Convertible Bonds to be repurchased and the purchase price will be determined by the reverse bookbuilding process.AdviserJ.P. Morgan Securities plc ("J.P. Morgan") is Sole Bookrunner on the Offering and Sole Dealer Manager on the Concurrent Repurchase.Key terms of the Convertible Bonds Issuer Telix Pharmaceuticals (Investments) Inc.GuarantorsTelix Pharmaceuticals Limited and Telix Pharmaceuticals (US) Inc.Expected Issue SizeUS$550 millionRankingDirect, unconditional, unsubordinated and unsecured obligations of the Issuer and GuarantorsMaturity Date5 yearsInvestor Put OptionAt the end of year 3Coupon / Yield 1.50 – 1.75%Conversion Premium35.0 – 37.5%Reference Share PriceThe clearing price of the Delta Placement – see belowDelta PlacementJ.P. Morgan will run a bookbuilding process to facilitate some or all of the hedging activity that may be executed by investors in the Convertible BondsThe clearing price of the Delta Placement will be used as the reference share price to determine the initial conversion price of the Convertible BondsThe manner of conducting the Delta Placement will be determined by J.P. Morgan in consultation with TelixConversion Price Adjustment Standard anti-dilutive adjustments including conversion price adjustment for all dividends paid by TelixListing SGX-STSelling RestrictionsReg S (Cat 2) onlyAbout Telix Pharmaceuticals Limited Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan, Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.Telix Investor Relations (Global)Ms. Kyahn WilliamsonSVP Investor Relations and
Corporate Communicationskyahn.williamson@telixpharma.comTelix Investor Relations (Australia)Ms. Charlene JawAssociate Director Investor
Relationscharlene.jaw@telixpharma.comTelix Investor Relations (U.S.)Ms. Annie KasparianDirector Investor Relations and Corporate Communicationsannie.kasparian@telixpharma.comThis announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.  Legal NoticesCautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including Australia, Singapore, and the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, including TLX101-Px and  TLX250-Px, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.Neither this announcement nor any copy hereof may be taken into or distributed in the United States.The information contained in this announcement is not for distribution, directly or indirectly, in or into the United States. The Convertible Bonds, the guarantees and the Ordinary Shares to be issued upon conversion of the Convertible Bonds have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States and they may not be offered or sold, resold, transferred or delivered, directly or indirectly, within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. The Convertible Bonds and the guarantees are being offered and sold solely outside the United States in an "offshore transaction" as defined in, and in reliance on Regulation S under the Securities Act.Nothing in this announcement or anything attached to it shall form the basis of any contract or commitment.The Concurrent Repurchase is not being made and will not be made, directly or indirectly, in or into the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. The Existing Convertible Bonds may not be tendered in the Concurrent Repurchase by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States as defined in Regulation S of the Securities Act. Any purported tender of Existing Convertible Bonds made by a person located in the United States will not be accepted.This communication may not be distributed to the press or other media or forwarded, photocopied, passed on or, in any other manner, transmitted to any other person. Non-compliance with the foregoing may constitute a violation of law. This information is subject to change.This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.©2026 Telix Pharmaceuticals Limited. All rights reserved.[1] Dr Behrenbruch holds an indirect interest.Logo - https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg



View original content:https://www.prnewswire.co.uk/news-releases/telix-refinances-convertible-bonds-302741511.html

Original: Telix Refinances Convertible Bonds

Regeneron, Telix strike radiopharmaceutical cancer deal worth up to $2.1bnApril 13, 2026 10:01 AM
IH Market News
Regeneron Pharmaceuticals (NASDAQ:REGN) has entered into a strategic collaboration with Telix Pharmaceuticals (NASDAQ:TLX) to develop and commercialize radiopharmaceutical therapies targeting cancer.As part of the agreement, Telix will receive an initial $40 million payment covering four early-stage therapeutic programs. Both companies will jointly fund development and split any resulting profits equally, while Telix will retain co-promotion rights for selected products. Regeneron also holds the option to extend the partnership to include four additional programs, which would trigger further upfront payments.If Telix opts out of co-funding any specific program, it would instead be eligible for milestone payments of up to $535 million tied to development and commercialization, along with low double-digit royalties on net sales. Across all programs, total potential milestone payments could reach $2.1 billion.The partnership brings together Regeneron’s expertise in antibody discovery and oncology with Telix’s capabilities in radiopharmaceutical development and manufacturing. The initial focus will be on multiple solid tumor targets derived from Regeneron’s antibody pipeline, including those developed using its VelocImmune platform.In addition to therapeutics, the companies plan to co-develop diagnostic imaging tools to support patient selection and monitor treatment response. Telix will lead the commercialization of these diagnostic products, while Regeneron will receive a share of the associated profits.“Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need,” said John Lin, Senior Vice President of Oncology & Antibody Technology Research at Regeneron.The collaboration also provides Regeneron with the opportunity to explore combining radiopharmaceutical approaches with its existing immunotherapy portfolio, particularly in indications such as lung cancer, where its PD-1 inhibitor is already established as a standard-of-care treatment.Regeneron Pharmaceuticals stock priceTelix Pharmaceuticals stock price

Original: Regeneron, Telix strike radiopharmaceutical cancer deal worth up to $2.1bn

Preso for today's meeting:

chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://ir.telixpharma.com/static-files/794bf44c-e52c-4d89-8d92-b864164e0e5f